Table 2 Summary of treatment-related, non-hematologic and non-biochemical, biochemical and haematological adverse events occurring in ≥2 patients who received treatment (All cohorts).
No. of patients AE affected n, (%) | Grade 1 (n = 24) | Grade 2 (n = 24) | Grade 3 (n = 24) | Grade 4 (n = 24) |
|---|---|---|---|---|
NON-HAEMATOLOGICAL AND NON-BIOCHEMICAL | ||||
Rash | 16 (67) | 4 (17) | 0 (0) | 0 (0) |
Dry skin | 2 (8) | 0 (0) | 0 (0) | 0 (0) |
Constipation | 2 (8) | 0 (0) | 0 (0) | 0 (0) |
Diarrhoea | 7 (29) | 1 (4) | 0 (0) | 0 (0) |
Nausea | 7 (29) | 2 (8) | 0 (0) | 0 (0) |
Vomiting | 5 (21) | 1 (4) | 1 (4) | 0 (0) |
Mucositis (including mouth pain and ulcers) | 5 (21) | 0 (0) | 0 (0) | 0 (0) |
Anorexia | 3 (13) | 1 (4) | 0 (0) | 0 (0) |
Fatigue | 4 (17) | 2 (8) | 2 (8) | 0 (0) |
Oedema | 4 (17) | 2 (8) | 0 (0) | 0 (0) |
Visual disturbance (including blurred vision) | 4 (17) | 0 (0) | 0 (0) | 0 (0) |
QTc prolongation | 4 (17) | 0 (0) | 0 (0) | 0 (0) |
BIOCHEMICAL | ||||
ALP increase | 2 (8) | 0 (0) | 0 (0) | 0 (0) |
ALT increase | 2 (8) | 0 (0) | 0 (0) | 0 (0) |
Hypoalbuminaemia | 0 (0) | 3 (13) | 2 (8) | 0 (0) |
HAEMATOLOGICAL | ||||
Anaemia | 1 (4) | 2 (8) | 2 (8) | 0 (0) |
